Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 19,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators, and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere.
Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With people, insight and focus on operational excellence, we work with HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference.
Patients first: Each of us, no matter what we do at Parexel, contributes to the development of a therapy that ultimately will benefit a patient. We take our work personally, we do it with empathy and we’re committed to making a difference.
Quality: From the smallest detail to the largest, we take quality seriously. We focus on the detail while never losing sight of the big picture to drive the best possible outcome.
Respect: We recognize and uphold the importance of all people, the way we do things, our quest for innovation, and most importantly, our patients.
Empowerment and accountability: We follow our hearts; we do the right thing and we have the courage to own the outcome.
Most service providers put their back into research. We put our hearts in as well.
We don’t just think differently about your project, we feel differently about it, too. When you face the complex problems involved in transforming scientific discovery into a new treatment, then getting that treatment into the hands of patients, you need a clinical research organization (CRO) partner who is invested at every level. A team of people who keep solving, improving, optimizing, and caring just as much as you do. No matter how long it takes, no matter the obstacles.
Clinical Research Services
To get new therapies to those who need them as quickly as possible, we research as efficiently as possible. From finding the right patients to operating in locations that suit them, we put our hearts into doing the most good at every point in the development timeline.
Over the years, we’ve learned a thing or two about how to navigate the development and approval landscape. That’s why we’re able to thoughtfully guide organizations through regulatory strategy, compliance, and partnerships. Together, we identify ways you can improve, then equip you with the tools to get there.
Whether you need a hand with a single part of a clinical study or with an entire portfolio, we can develop an outsourcing model to fit the task at hand.
With more than three decades of experience, Parexel’s medical communications services help ensure that your products benefit from insightfully conveyed data and communications excellence.
Parexel’s innovation engine aspires to be the vanguard in retooling the way that therapies are developed and ultimately delivered to patients.
Real-World Data Sciences
In today’s landscape, regulatory approval isn’t the end of the drug development process, it’s just the beginning. That’s why, we provide a customized approach that is designed to help you get fit-for-purpose data and the insights that you need – not just terabytes of data to support value demonstration for payers, providers, and patients.
Meet The CEO
Jamie Macdonald, Chief Executive Officer
Jamie Macdonald is the Chief Executive Officer of Parexel. He has more than 25 years of experience in leading global biopharmaceutical services companies.
Prior to joining Parexel, Mr. Macdonald served as Chief Executive Officer of INC Research, now known as Syneos Health, from January 2013 through September 2016, where he led the company through a successful Initial Public Offering in 2014. Mr. Macdonald also served as INC’s Chief Operating Officer from July 2011 through December 2012, and previously held several leadership positions in the biopharmaceutical services industry, including Senior Vice President and Head of Global Project Management at Quintiles, now known as IQVIA. Prior to this, he held various senior operational and finance roles at Quintiles. He has previously served on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and as its Chairman in 2015. Mr. Macdonald’s recent experience also includes serving as Chairman of the Board for Certara, a drug development consultancy with solutions spanning discovery, preclinical, and clinical drug development, from 2017 to 2018.
Mr. Macdonald began his career in the pharmaceutical industry with Syntex Corporation (acquired by Roche Holdings, Inc.). A native of Scotland, he holds a B.A. in Economics from Heriot-Watt University in Edinburgh, Scotland, and is a qualified Chartered Management Accountant (ACMA).
“Throughout our years helping discoveries come to market, one thing has remained constant – the more patient-focused the process, the better. That’s why all our services take patient input to heart before, during, and after a clinical study.”